Therefore 89% are positive. Analysts are turning out to be more optimistic than before, with 7 of analysts who cover AtriCure, Inc. AtriCure has an average rating of "Buy" and an average price target of $25.83. The firm has "Buy" rating given on Thursday, July 27 by Canaccord Genuity. Canaccord Genuity maintained the shares of ATRC in report on Tuesday, October 6 with "Buy" rating. As per Tuesday, March 29, the company rating was initiated by Northland Capital. The stock is trading for about -10.64% less than its 52-week high. They now have a Dollars 30 price target on the stock. Canaccord Genuity has "Buy" rating and $28.0 target. The rating was maintained by Needham on Monday, August 21 with "Buy". The rating was maintained by Needham on Tuesday, October 6 with "Buy". The firm earned "Buy" rating on Wednesday, July 29 by Needham. The first sale was made at $23.44 but later the stock became weaker, and closed with a fall of -4.01%. It was reported on Oct, 9 by Barchart.com. Next quarter's EPS is expected be $-0.19 with next year's EPS anticipated to be $-0.71. The stock decreased 0.54% or $0.59 during the last trading session, reaching $109.06. It has outperformed by 16.96% the S&P500.
Since May 1, 2017, it had 0 insider buys, and 7 selling transactions for $17.28 million activity. Bronfman E.l. Rothschild, L.p. now holds 393 shares valued at $10,000. Prudential Financial had 35 analyst reports since August 6, 2015 according to SRatingsIntel. The stock's market capitalization is $772.86 million. The rating was upgraded by Bank of America on Friday, November 18 to "Buy". The company was maintained on Friday, August 5 by Stifel Nicolaus.
Savings Bank Of Montreal Can accumulated 0% or 10,462 shares. 2,154 are held by Great West Life Assurance Company Can. The rating was maintained by RBC Capital Markets with "Hold" on Monday, June 26. BidaskClub lowered AtriCure from a strong-buy rating to a buy rating in a research report on Monday, July 24th.
Investors sentiment increased to 1.2 in 2017 Q2. With short interest at 1,992,946 and short average daily volume at 247,574, the short-interest ratio is 8.0 and the percentage of shorted shares is 0.06% as of September 15. It improved, as 63 investors sold PG shares while 714 reduced holdings. 74 funds opened positions while 270 raised stakes. Vanguard reported 1.45M shares. The New York-based Citigroup has invested 0.15% in Procter & Gamble Co (NYSE:PG). Bouchey Fincl Group Inc Ltd has 0.08% invested in Procter & Gamble Co (NYSE:PG) for 2,915 shares. CA Dafna Capital Management Llc have 10.61% of its portfolio for 487946 shares. Northern Tru holds 427,560 shares. Victory Cap Management Incorporated holds 0.07% or 1.32 million shares. Point72 Asset Mngmt Lp has 0.02% invested in AtriCure Inc. Highlander Capital Management Lc holds 0.23% of its portfolio in AtriCure Inc. Usa Portformulas Corp invested in 0.71% or 33,721 shares. State Of Wisconsin Invest Board has invested 0.22% in Prudential Financial Inc (NYSE:PRU). Jefferies Group Inc Ltd Limited Liability Company holds 0.04% or 69,091 shares in its portfolio. Osterweis Cap Management Inc reported 82,298 shares. Voya Investment Management LLC raised its stake in shares of AtriCure by 7.9% in the second quarter. 3,879 Procter & Gamble Co (NYSE:PG) shares with value of $334,265 were sold by Skoufalos Ioannis. Citrix Sys Inc Com (NASDAQ:CTXS) was reduced too. AtriCure Inc. (NASDAQ:ATRC) has risen 53.35% since October 9, 2016 and is uptrending. (NASDAQ:ATRC) for 54,700 shares. AlphaOne also assigned news headlines about the medical device company an impact score of 41 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days. $1.24 million worth of AtriCure Inc. 58,112 shares were sold by Seith Douglas J, worth $1.24M. It has ranged in price between $22.38-$22.82 after having started the session at $22.5 as compared to the previous trading day's close of $22.5. They expect $1.05 EPS, down 9.48% or $0.11 from last year's $1.16 per share. It has outperformed by 36.65% the S&P500.
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The company has market cap of $25.26 billion. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It now has negative earnings. AtriCure's Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib.
Investors sentiment increased to 0.94 in Q2 2017. Its up 0.10, from 1.15 in 2017Q1.
Atricure, Inc stake is new for [reportingPerson]. 21 funds opened positions while 29 raised stakes.
03/02/2015 - AtriCure, Inc. was downgraded to "underperform" by analysts at Zacks. (NASDAQ:ATRC) for 137,296 shares. (NASDAQ:ATRC) or 10,000 shares.
AtriCure (NASDAQ ATRC) opened at 22.435 on Monday.
Filings show 119 investors own Atricure, Inc. (NASDAQ:ATRC) to report earnings on October, 26. (NASDAQ:ATRC) for 12,050 shares. The medical device company reported ($0.21) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.26) by $0.05. Moreover, Eventide Asset Mgmt Ltd Company has 0.27% invested in AtriCure Inc.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.